Trial reportScience translational medicine2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.
Abstract readRandomized Controlled Trial
In one paragraph
Trial report in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.Human vaccines & immunotherapeutics · 2026Trial
- Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.Nature communications · 2025Trial
- Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.Nature communications · 2025Trial
- Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.Nature communications · 2024Trial
- Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.Nature communications · 2024Trial
- Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.Nature communications · 2024Trial
- Trial
- Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.The Lancet. Microbe · 2023Trial
- Immune correlates of risk for SARS-CoV-2 infection in children: a prospective, community-based cohort study.Nature communications · 2026Article
- Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.NPJ vaccines · 2026Article
- SARS-CoV-2 vaccination and infection elicit cross-neutralizing responses against clade 3 and 4 sarbecoviruses.Nature communications · 2026Article
- Article
- Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan-Coronavirus Vaccine Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.iScience · 2025Article
- Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.Nature communications · 2025Article
- Correlates of risk of respiratory syncytial virus disease: a prospective cohort study.Nature communications · 2025Article
- Replicated blood-based biomarkers for myalgic encephalomyelitis not explicable by inactivity.EMBO molecular medicine · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
David BenkeserDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-1019-8343
David C MontefioriDepartment of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-0856-6319
Adrian B McDermottVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0616-9117
Youyi FongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-4230-6863
Holly E JanesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Weiping DengModerna Inc., Cambridge, MA 02139, USA.
Honghong ZhouModerna Inc., Cambridge, MA 02139, USA.
Christopher R HouchensBiomedical Advanced Research and Development Authority, Washington, DC 20201, USA.ORCID 0000-0001-8125-4173
Karen MartinsBiomedical Advanced Research and Development Authority, Washington, DC 20201, USA.ORCID 0000-0001-6536-3492
Lakshmi JayashankarBiomedical Advanced Research and Development Authority, Washington, DC 20201, USA.ORCID 0000-0003-0384-2388
Flora CastellinoBiomedical Advanced Research and Development Authority, Washington, DC 20201, USA.ORCID 0000-0002-3432-9846
Britta FlachVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Bob C LinVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-1373-1406
Sarah O'ConnellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Charlene McDanalDepartment of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-4177-5561
Amanda EatonDepartment of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-3064-2947
Marcella Sarzotti-KelsoeDepartment of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-7392-6072
Yiwen LuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Chenchen YuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Bhavesh BorateVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lars W P van der LaanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Nima S HejaziVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-7127-2789
Avi KennyDepartment of Biostatistics, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-9465-7307
Marco CaroneDepartment of Biostatistics, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-2106-0953
Brian D WilliamsonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-7024-548X
Jennifer GarverBattelle, West Jefferson, OH 43162, USA.ORCID 0000-0003-2610-8784
Erin AltonenBattelle, West Jefferson, OH 43162, USA.ORCID 0000-0003-1716-7336
Thomas RudgeBattelle, West Jefferson, OH 43162, USA.ORCID 0000-0002-8801-8744
Chuong HuynhBiomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Jacqueline MillerModerna Inc., Cambridge, MA 02139, USA.ORCID 0000-0002-7083-2182
Hana M El SahlyBaylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-0489-0074
Lindsey R BadenBrigham and Women's Hospital, Boston, MA 02115, USA.
Sharon FreyDepartment of Internal Medicine, Saint Louis University, St. Louis, MO 63110, USA.
Elissa MalkinVaccine Research Unit, School of Medicine and Health Sciences, George Washington University, Washington, DC 20052, USA.ORCID 0000-0003-0943-5433
Stephen A SpectorDivision of Pediatric Infectious Diseases, University of California, San Diego, La Jolla, CA 92093, USA.
Michele P AndrasikVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1952-7825
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1279-3741
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-2179-2436
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-9480-2714
Lindsay N CarppVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-0333-5925
Rolando PajonModerna Inc., Cambridge, MA 02139, USA.ORCID 0000-0002-5155-5079
Dean FollmannBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-4073-0393
Ruben O DonisBiomedical Advanced Research and Development Authority, Washington, DC 20201, USA.ORCID 0000-0001-6137-8312
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3090-7282
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-2662-9427
Immune Assays
Moderna Inc.
Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE)
United States Government (USG)/CoVPN Biostatistics Teams
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MLeadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MVaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6MTesting of Blood Samples for Immune Response and Vaccine ResearchZIAAI005073 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$23.4MStatistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MPPE RequestS10AI174104 · NIAID · FRED HUTCHINSON CANCER CENTER · PI COREY, LAWRENCE · 2023 to 2023
$1.4MNIAID NIH HHS R37 AI054165NIAID NIH HHS S10 AI174104NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI148684NIAID NIH HHS UM1 AI148685NIH HHS S10 OD028685
Abstract
The best assay or marker to define mRNA-1273 vaccine-induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA-1273 COVID-19 vaccine or placebo. We previously assessed IgG binding antibodies to the spike protein (spike IgG) or receptor binding domain (RBD IgG) and pseudovirus neutralizing antibody 50 or 80% inhibitory dilution titer measured on day 29 or day 57, as correlates of risk (CoRs) and CoPs against symptomatic COVID-19 over 4 months after dose. Here, we assessed a new marker, live virus 50% microneutralization titer (LV-MN
Indexed as
2019-nCoV Vaccine mRNA-1273COVID-19Antibodies, NeutralizingAntibodies, ViralHumansImmunoglobulin GVaccine Efficacy2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralImmunoglobulin G
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.